89Zr标记的白蛋白结合VHH构造物的亲和性和形式依赖的药理动力学
Simon Leekens1, Peter Casteels2, Tom Van Bogaert2
1Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium.
Pharmaceuticals (Basel, Switzerland)
|January 28, 2026
概括
优化纳米体 (VHH) 放射性药物包括平衡蛋白结合亲和力和分子大小. 高亲和度 (纳米) 最大限度地提高了循环时间,而大小影响了较低亲和度的药理动力学.
科学领域:
- 放射性药物开发的发展.
- 分子工程是分子工程.
- 药理动力学 药理动力学
背景情况:
- 纳米体 (VHH) 分子是有前途的放射性药物载体,但患有快速清除和脏保留.
- 专结合用于扩大血液循环,但亲和力和格式效应尚不清楚.
研究的目的:
- 系统地评估蛋白结合 afinity 和 valency 如何影响 VHH 的药理动力学.
- 定义VHH属性与它们在生物体中的行为之间的关系.
主要方法:
- 工程化单价和双价VHH结构具有不同的蛋白结合亲缘关系 (纳米到微分子).
- 采用DFO*结合物用于统一的-89标签.
- 在小鼠中通过连续取血样和正子发射断层扫描评估药理动力学.
主要成果:
- 与对照组相比,所有结合白蛋白的VHH都显示了系统暴露的增加和脏吸收的减少.
- 纳米分子亲和结合剂达到最大暴露,没有进一步的改善超出了100nm亲和值.
- 价值效应仅在较低的亲缘关系下显著,增加了全身暴露和吸收.
结论:
- 结合白蛋白有效调整VHH的药理动力学以一种依赖于亲和力的方式.
- 存在一种亲和度值,在这个值以上,分子格式对VHH排放变得不那么重要.
- 在这个门以下,分子格式显著影响系统和脏VHH行为.
相关概念视频
Chronopharmacokinetics: Time-Dependent Pharmacokinetics
411
Chronopharmacokinetics studies the temporal change in drug absorption and elimination. These changes can be cyclical or non-cyclical. Cyclical changes occur over a regular interval, while non-cyclical changes occur over a longer, irregular period.
Time-dependent pharmacokinetics refers to non-cyclical changes in drug rate processes over a period of time. It can lead to nonlinear pharmacokinetics, where the relationship between drug concentration and time is not proportional. Non-cyclical...
Time-dependent pharmacokinetics refers to non-cyclical changes in drug rate processes over a period of time. It can lead to nonlinear pharmacokinetics, where the relationship between drug concentration and time is not proportional. Non-cyclical...
411
Affinity and Avidity
38.7K
Overview
38.7K
Physiological Pharmacokinetic Models: Assumption with Protein Binding
249
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
249
Electron Affinity
43.3K
The electron affinity (EA) is the energy change for adding an electron to a gaseous atom to form an anion (negative ion).
43.3K
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
610
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
610
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
666
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
666


